Provectus Biopharmaceuticals: 10% owner Pershing Edward received 7,599 shares

What happened

• Pershing Edward, identified as a 10% owner, converted the outstanding 8% unsecured convertible promissory note (the "2025 Note") into 7,599 shares of Series D-1 Convertible Preferred Stock; the Form 4 reports those 7,599 derivative shares were acquired at $0 on Oct 23, 2026.

Key details

• Transaction date: Oct 23, 2026. Transaction code: M (exercise or conversion of a derivative).
• Shares acquired: 7,599 shares of Series D-1 Convertible Preferred Stock at $0 per share (reported value $0).
• Conversion mechanics: each Series D-1 preferred share is convertible into 10 shares of common stock, so 7,599 preferred shares would convert into 75,990 common shares (per the filing).
• Conversion price context: the 2025 Note could be converted at $2.862 per Series D-1 preferred share and automatically converted twelve months after issue; the filing states the 2025 Note converted into 7,599 Series D-1 shares on Oct 23, 2026.
• Shares owned after the transaction: not stated in the provided filing details.
• Filing date and timeliness: Form filed on Oct 23, 2026; no late filing indicated in the provided data.

Why it may matter

• This was a conversion of debt into preferred stock (a derivative conversion), not a purchase or sale on the open market.
• The reporting person is a 10% owner, which denotes a large holder rather than an executive title in the filing.
• A filing does not show why the insider traded or why the company acted.